Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
It is estimated that one-third of our country’s population has some form of these disorders
A first for the Asian market, addressing the health spends needs of over 200 million households.
Subscribe To Our Newsletter & Stay Updated